BioNJ Members in the News


Biolines Weekender
is BioNJ’s weekly e-newsletter featuring the latest happenings in R&D, as well as the incredible innovation coming from New Jersey’s robust life sciences ecosystem.

Weekender 7/14/17

Welcome to the latest edition of the BioLines WeekenderIt has been a busy week for the FDA, bringing new therapies and cures to Patients around the globe…….Read the full article

Weekender 6/23/17

What an exciting week we’ve had showcasing New Jersey’s unprecedented life sciences talent, innovative biopharma companies and world-renowned research institutions….... Read the full article

Weekender 6/9/17

As part of BioNJ’s ongoing “Voice of Value” initiative — featuring educational tools, resources and communication pieces — we created two useful primers.... Read the full article

Weekender 5/26/17

This week BioNJ held its Seventh Annual BioPartnering Conference, in partnership with J.P. Morgan, at Rutgers University. It was a wonderful reminder….... Read the full article

Weekender 5/12/17

The important work that our Members do each and every day — developing new therapies, cures and hope — is core to BioNJ’s mission to ensure that Patients are Paramount….... Read the full article

Weekender 4/28/17

We have an exciting few weeks ahead of us with a wide variety of educational programs planned. Join New Jersey’s life sciences community….... Read the full article

Weekender 4/17/17

With its unparalleled wealth of clinical and commercial development expertise, marked by a robust infrastructure of innovator companies, clinical research organizations, academic and health centers and related operations, New Jersey continues to be….... Read the full article

Weekender 3/31/17

A number of New Jersey companies have received new FDA drug approvals, including Sanofi and Regeneron for Dupixent® (dupilumab), the first targeted biologic….... Read the full article

Weekender 3/10/17

BioNJ is excited to designate March as New Jersey Life Sciences Month. During the month, numerous industry activities throughout the State will showcase the contributions that New Jersey’s life sciences ecosystem is making to advance….... Read the full article

Weekender 2/24/17

This edition of BioLines Weekender is in honor of the Rare Disease community. BioNJ is pleased to participate in Rare Disease Day 2017 in Trenton on Monday, February 27, at the New Jersey Business and Industry Association (NJBIA). Bringing together….... Read the full article

Weekender 2/10/17

The industry came out to honor New Jersey’s innovative life sciences companies and leaders, as well as the Patients who inspire them, last Thursday night at BioNJ’s 24th Annual Gateway Gala and Innovation Celebration. From a moving Keynote….... Read the full article

Weekender 1/20/17

From the enrollment of new Patients in clinical studies and the reporting of positive results, to the EU and FDA approval of new drugs, bringing therapies and cures to Patients….... Read the full article

Weekender 1/6/17

Because BioNJ’s mission is to help our Members help Patients, we are pleased to announce that BioNJ’s tagline Because Patients Can’t Wait® has been registered with….... Read the full article

Weekender 12/16/16

This week we celebrated the signing of the 21st Century Cures Act into law by President Barack Obama. Our 8-year old Patient advocate “Magic” Max Schill was on hand with the President and Vice President….... Read the full article

Weekender 12/2/16

In honor of New Jersey’s unparalleled medical innovation and the Patients who inspire them, registration is open for BioNJ’s 24th Annual Gateway Gala & Innovation Celebration, taking place on February 2, 2017. The inspirational evening will feature a networking reception and dinner program, including the presentation….... Read the full article

Weekender 11/18/16

Welcome to the latest edition of BioLines Weekender, highlighting the innovation taking place in the State, including progress in numerous clinical trials, drug development, corporate partnering and research developments. Personifying what the life sciences industry is all about and the extraordinary value of medical innovation, the unstoppable Don Wright, The Marathon Man and 2015 BioNJ Annual Meeting Speaker is on target to finish….... Read the full article

Weekender 11/4/16

Congrats to BioNJ Board Member Anthony Marucci and Celldex Therapeutics on the announcement of the intended acquisition of Kolltan Pharmaceuticals. Anthony and Celldex are 2005 spinouts of the former Medarex which was later acquired by Bristol-Myers Squibb….... Read the full article

Weekender 10/21/16

Welcome to this week’s edition of our newly designed BioLines Weekenderfeaturing the latest news on New Jersey’s innovative biopharma community. From Eli Lilly and Company‘s FDA approval of LARTRUVO™ in combination with Doxorubicin for soft tissue sarcoma to the Fast Track designation by the FDA….... Read the full article

Weekender 10/7/16

Welcome to the newly designed BioLines Weekender. Our new format allows for easier reading on mobile devices. And, our user-friendly links allow you to easily register for BioNJ events, as well as add them to your Outlook calendar. To access full articles, please click on the article’s title….... Read the full article

Weekender 9/23/16

Welcome to an early edition of BioLines Weekender as this Friday, the BioNJ Team is headed to BioNJ’s CEO Summit at the Bridgewater Marriott. An industry trademark event, the CEO Summit will bring together nearly 300 biotech/pharma C-Suite leaders and their teams, investors, entrepreneurs, academics and other...... Read the full article

Weekender 9/9/16

In tribute to our industry as well as New Jersey, BioNJ and our 4th Annual CEO Summit, BioNJ’s President and CEO, Debbie Hart; Lt. Governor Kim Guadagno; along with Board members and other industry members had the honor yesterday of ringing the opening bell of the NASDAQ..... Read the full article

Weekender 8/26/16

Many of New Jersey’s innovative biopharma companies advanced recently on their way to new FDA drug approvals, including BioNJ Members Scynexis, Soligenix and Eli Lilly & Co., giving fresh hope to Patients and their families ... Read the full article

Weekender 8/12/16

In this week’s edition of the BioLines Weekender we introduce a new section entitled “Economic Developments.” In addition to highlighting the numerous companies moving to the Garden State, we will be spotlighting those expanding their footprint, such as BioNJ Member Allergan. .... Read the full article

 Interested in reading more? Visit the Weekender Newsletter Archive.



BioNJ Member press releases and upcoming events.

February 13, 2017 –Imbue Creative Moves to Former Lambertville Opera House

Ewing/Lambertville, NJ  – Imbue Creative has moved their headquarters into the first floor of the striking circa 1860 Italian Revival building at 71 North Main Street in Lambertville, after spending over six months lovingly restoring it…..Read the full article

June 22, 2016 – Imbue Creative Returns to Its Delaware River Roots in Historic MacDonald Kitchen and Bath Building

Ewing/Lambertville, NJ  – The first floor of the striking circa 1860 Italian Revival building at 71 North Main Street in Lambertville, most recently the home of MacDonald Kitchen and Bath Designs, has stood empty for three years. Soon, it will be the new home of Imbue Creative, a branding and creative services agency that is in the process of revitalizing the building….Read the full article

May 3, 2016 – Acumen BioPharma Launches New Business Unit, Expands Capabilities into Continuous Pharmaceutical Manufacturing

PRINCETON, NJ – “The launch of a new business unit tremendously expands our capabilities in the analysis, engineering and implementation of continuous pharmaceutical manufacturing,” states Daisy Rivera-Muzzio….Read the full article

May 3, 2016 – Quantex Laboratories awarded ISO/IEC 17025:2005 accreditation

CRANBURY, NJ – “We’re proud of our ISO 17025 accreditation as it reflects the broad scope of our capabilities. Also, it’s gratifying to know that we’re one of the very few labs, nationally, to hold accreditation for Elemental Impurities.” Quantex Laboratories’ President and CEO, James Menoutis, PhD, reacts to the lab’s accreditation achievement…Read the full article

Mar. 23, 2016 – JBK Associates International Expands in Geneva

Englewood Cliffs, N.J./March 23, 2016 – The executive talend solutions firm JBK Associates International has opened an office in Geneva, Switzerland, as part of the firm’s expanding international practice. Under the leadership of Elaine L. Arozarena …Read the full article

Mar. 17, 2016 – Women’s Venture Fund Names Julie B. Kampf to Board of Directors

Englewood Cliffs, N.J./March 17, 2016 – The Women’s Venture Fund (WVF) has appointed Julie B. Kampf to its board of directors …Read the full article

Dec. 16, 2015 – Julie B. Kampf Among Women of Influence Recognized by New York Business Journal

Englewood Cliffs, N.J./December 16, 2015 – Julie B. Kampf, CEO & Chief Possibilities Officer of the executive talent solutions firm JBK Associates International, has been named one of New York Business Journal’s 2016 Women of Influence Award honorees.  Kampf is among 79 New York metropolitan area …Read the full article

Nov. 15, 2015 – Triple Play: Why life sciences industry has bright future in N.J.

Triple Play: Why life sciences industry has bright future in N.J. | NJBIZ We asked John for three reasons why the future is bright for life sciences in New Jersey and here is what he had to say…Read the full article

Nov. 10, 2015 – Celator® Pharmaceuticals Presents Positive Results from R&D Programs

EWING, N.J., Nov. 10, 2015 — Celator Pharmaceuticals, Inc. announced the presentation of positive results from its CombiPlex® technology platform applied to drug combinations incorporating molecularly targeted agents (MTAs) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics… Read the full article

Oct. 21, 2015 – Celator® Pharmaceuticals Announces VYXEOS™ (CPX -351) Shows No QT/QTc Interval Prolongation in an Intensive QT/QTc Study

EWING, N.J., Oct. 21, 2015 — Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that a Phase 2 pharmacokinetic and pharmacodynamics (PK/PD) study evaluating the effects of VYXEOS™ (CP-X351) on cardiac depolarization/repolarization has concluded and VYXEOS did not prolong the QT/QTc interval… Read the full article

Interested in reading more? View BioNJ Members in the News Archive.